摘要
化疗是晚期肺癌的主要治疗方式，但对于非小细胞肺癌及复发的小细胞肺癌化疗有效率仍较低．肿瘤细胞的多药耐药性是化疗失败的主要原因。目前认识到肿瘤细胞的耐药是一个复杂的多因素参与过程，目前已证实一些耐药相关性生物标志物与肿瘤的化疗敏感性预测、患者预后相关。基于生物标志物的肺癌化疗方案选择将为个体化治疗带来希望。
Chemotherapy is the basic therapy in advanced lung cancer patients. But the multidrug resistance is the key factor which reduces the efficacy of the chemotherapy in patients with non-small cell lung cancer and small cell lung cancer recrudescence. Many factors take part in the multidrug resistance of tumor cells. A series of biomarkers have been confirmed to have the value in the prediction of the drug sensitivity and the prognostic. The chemotherapy protocol on the basis of biomarker will contribut to the individualized treatment.
出处
《国际呼吸杂志》
2012年第4期304-311,共8页
International Journal of Respiration
关键词
肺癌
化疗
多药耐药
生物标志物
Lung cancer
Chemotherapy
Multidrug resistance
Biomarker
